Thus, acting on the epigenetic processes to increase MBNL1 transcription and restore free MBNL1 protein level, may be considered as a potential new therapeutic target to restore normal splicing and reduce DM1 symptoms. This evidence concerns the gene MBNL1 and myotonic dystrophy type 1.